Animal models for COVID-19César Muñoz‐Fontela, Chien‐Te K. Tseng, William E. Dowling et al.|Nature|2020Cited by 877
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposingLaura Riva, Sumit K. Chanda, Shuofeng Yuan et al.|Nature|2020Cited by 856
A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylacticsLonglong Si, Donald E. Ingber, Haiqing Bai et al.|Nature Biomedical Engineering|2021Cited by 433
Proteomic and genetic analyses of influenza A viruses identify pan-viral host targetsKelsey M. Haas, Steven M. Wolinsky, Nevan J. Krogan et al.|Nature Communications|2023Cited by 61
Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm TrialAndrew R. Branagan, Madhav V. Dhodapkar, Eamon Duffy et al.|Clinical Lymphoma Myeloma & Leukemia|2017Cited by 48